Theranos told its investors that it has reached a tentative settlement with former business partner Walgreens and will pay out less than $30 million in the agreement, The Wall Street Journal reports.

The drugstore giant filed a searing lawsuit late last year against the beleaguered blood-testing company. Walgreens was seeking $140 million —presumed to be the amount it invested in a 2012 deal with Theranos to host blood-testing ‘Wellness Centers’ in its stores. In court filings, Walgreens alleged that Theranos had broken all its promises and “failed to meet the most basic quality standards and legal requirements” of their partnership.

Today’s reported settlement is not final, and the terms could change. But if they do not, it would mean that Walgreens will be out more than $100 million from their dealings with Theranos.

On the other hand, the small price tag is good news for Theranos, which is strapped for cash. The company was forced out of the clinical blood testing business by federal regulators last year after it was clear that its testing and technology were critically flawed . The company has since switched to blood testing device manufacturing and has been settling its mounting lawsuits. Those include suits filed by former investors and the state of Arizona , as Ars has previously reported.

According to the WSJ, Theranos recently told investors it has only around $54 million in cash, despite at one point being valued at $9 billion. The company’s monthly expenditures are said to be around $10 million—much of it for legal fees—and last year it cut its staff from roughly 900 to 170. The WSJ also reports that Theranos intends to ask investors for $50 million in loans and hopes to raise $150 to $200 million in a funding round next year.

Theranos is still facing investigations by the Securities and Exchange Commission and Justice Department.

Theranos did not respond to Ars’ request for comment. A representative for Walgreens declined to comment.